Lane 1: JAR cell lysate
Lane 2: SK-Br-3 cell lysate
Mouse monoclonal primary
CEACAM6 Mouse Monoclonal Antibody [A1E2] (EM1901-68)
Recombinant protein within human ceacam6 aa 1-160 / 344.
JAR cell lysate, SK-Br-3 cell lysate, A549, HT-29, MCF-7, human lung tissue, human colon tissue, human colon carcinoma tissue, SW620.
Store at +4C after thawing. Aliquot store at -20C. Avoid repeated freeze / thaw cycles.
1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.
Protein A affinity purified.
Predicted band size 37 kDa
Carcinoembryonic antigen related cell adhesion molecule 6 antibody; Carcinoembryonic antigen related cell adhesion molecule 6 (non specific cross reacting antigen) antibody; Carcinoembryonic antigen-related cell adhesion molecule 6 antibody; CD 66c antibody; CD66c antibody; CD66c antigen antibody; CEA LIKE PROTEIN antibody; CEACAM 6 antibody; CEACAM6 antibody; CEAL antibody; CEAM6_HUMAN antibody; MGC93832 antibody; NCA antibody; Non specific cross reacting antigen antibody; Non-specific crossreacting antigen antibody; Normal cross reacting antigen antibody; Normal cross-reacting antigen antibody
Belongs to the immunoglobulin superfamily. CEA family.
Expressed in neutrophils. Expressed in columnar epithelial and goblet cells of the colon. Expressed in numerous tumor cell lines (at protein level).
Cell membrane, apical cell membrane, cell surface.
Cell surface glycoprotein that plays a role in cell adhesion and tumor progression. Intercellular adhesion occurs in a calcium- and fibronectin-independent manner. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM5 and CEACAM8. Heterophilic interaction with CEACAM8 occurs in activated neutrophils. Plays a role in neutrophil adhesion to cytokine-activated endothelial cells. Plays a role as an oncogene by promoting tumor progression; positively regulates cell migration, cell adhesion to endothelial cells and cell invasion. Also involved in the metastatic cascade process by inducing gain resistance to anoikis of pancreatic adenocarcinoma and colorectal carcinoma cells.